Susan Halabi CV

Journal article J Clin Oncol · September 20, 2012 Featured Publication PURPOSE: Lactate dehydrogenase (LDH) is an enzyme involved in anaerobic glycolysis and regulated by the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR)-containing complex 1 (PI3K/Akt/TORC1) pathway as well as tumor hypoxia/necrosis. ... Full text Link to item Cite

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Journal article J Clin Oncol · May 1, 2012 Featured Publication PURPOSE: A randomized, placebo-controlled study based on preclinical and clinical data that supports the potential role of vascular endothelial growth factor in prostate cancer was performed to evaluate the addition of bevacizumab to standard docetaxel and ... Full text Link to item Cite

Design issues in randomized phase II/III trials.

Journal article J Clin Oncol · February 20, 2012 Featured Publication Phase II trials are used to show sufficient preliminary activity of a new treatment (in single-arm designs or randomized screening designs) or to select among treatments with demonstrated activity (in randomized selection designs). The treatments prioritiz ... Full text Link to item Cite

Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease.

Journal article Stat Med · January 13, 2012 Featured Publication The analysis of case-control studies with matched controls per case is well documented in the medical literature. Of primary interest is the estimation of the relative risk of disease. Matched case-control studies fall into two scenarios: the probability o ... Full text Link to item Cite

A min-max combination of biomarkers to improve diagnostic accuracy.

Journal article Stat Med · July 20, 2011 Featured Publication Diagnostic accuracy can be improved considerably by combining multiple biomarkers. Although the likelihood ratio provides optimal solution to combination of biomarkers, the method is sensitive to distributional assumptions which are often difficult to just ... Full text Link to item Cite

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

Journal article J Natl Cancer Inst · July 7, 2010 Featured Publication BACKGROUND: Tamoxifen use has been associated with increased risk of thromboembolic events (TEs) in women with breast cancer and women at high risk for the disease. Factor V Leiden (FVL) is the most common inherited clotting factor mutation and also confer ... Full text Link to item Cite

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

Journal article J Clin Oncol · May 1, 2010 Featured Publication PURPOSE: Bevacizumab is an antibody that binds vascular endothelial growth factor and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-alpha) is the historic standard initial treatment for RCC. A prospective, randomized, phase II ... Full text Link to item Cite

The importance of identifying and validating prognostic factors in oncology.

Journal article Semin Oncol · April 2010 Featured Publication Prognosis plays a vital role in patient management and decision making. The assessment of prognostic factors, which relate baseline clinical and experimental covariables to outcomes, is one of the major objectives in clinical research. Historically, the im ... Full text Link to item Cite

Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

Journal article J Clin Oncol · June 10, 2009 Featured Publication PURPOSE: To explore whether progression-free survival (PFS) or biochemical PFS can be used as a predictor of overall survival (OS) and to investigate the dependence between PFS and OS in men with castrate-resistant prostate cancer. PATIENTS AND METHODS: Da ... Full text Link to item Cite

Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

Journal article J Natl Cancer Inst · February 18, 2009 Featured Publication BACKGROUND: Multiple lines of evidence indicate that aspirin has an antineoplastic effect in the large bowel. Randomized clinical trials have been conducted to evaluate the effectiveness of aspirin for reducing the risk of colorectal adenomas. A meta-analy ... Full text Link to item Cite

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Journal article J Clin Oncol · November 20, 2008 Featured Publication PURPOSE: Bevacizumab is an antibody that binds to vascular endothelial growth factor (VEGF) and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN) is a historic standard first-line treatment for RCC. A prospective, randomized phas ... Full text Link to item Cite

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

Journal article J Clin Oncol · May 20, 2008 Featured Publication PURPOSE: Pain from castration-refractory prostate cancer (CRPC) bone metastases is a common event. Although it is assumed that pain represents an adverse prognostic factor, this variable has not been extensively evaluated. The objective of this study was t ... Full text Link to item Cite

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Journal article J Clin Oncol · March 1, 2008 Featured Publication PURPOSE: To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone. METHODS: A committee of investigators experienced in conducting trials for pro ... Full text Link to item Cite

Sample size determination for comparing several survival curves with unequal allocations.

Journal article Stat Med · June 15, 2004 Featured Publication Ahnn and Anderson derived sample size formulae for unstratified and stratified designs assuming equal allocation of subjects to three or more treatment groups. We generalize the sample size formulae to allow for unequal allocation. In addition, we define t ... Full text Link to item Cite

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Journal article J Clin Oncol · March 15, 2004 Featured Publication PURPOSE: Antiandrogen withdrawal (AAWD) results in a prostate-specific antigen (PSA) response (decline in PSA level of > or =50%) in 15% to 30% of androgen-independent prostate cancer (AiPCa) patients. Thereafter, adrenal androgen ablation with agents such ... Full text Link to item Cite

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.

Journal article J Clin Oncol · February 1, 2004 Featured Publication PURPOSE: To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA). HYPOTHESIS: A clinical states framework was used to address the hypothesis that definitive phase III trials could not be conducte ... Full text Link to item Cite

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

Journal article J Clin Oncol · July 15, 2003 Featured Publication PURPOSE: The mechanisms responsible for prostate cancer androgen independence are diverse. Mutations of the androgen receptor (AR) gene that broaden ligand specificity have been implicated. Bone marrow specimens containing prostate tumor were obtained from ... Full text Link to item Cite

Analysis of survival data with missing measurements of a time-dependent binary covariate.

Journal article J Biopharm Stat · May 2003 Featured Publication The objective of this study was to investigate the influence of the number and timing of a binary time-dependent covariate on the bias using the last-observation carried forward in the proportional hazards model. Under various assumptions of censoring rate ... Full text Link to item Cite

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

Journal article J Clin Oncol · April 1, 2003 Featured Publication PURPOSE: To develop and validate a model that can be used to predict the overall survival probability among metastatic hormone-refractory prostate cancer patients (HRPC). PATIENTS AND METHODS: Data from six Cancer and Leukemia Group B protocols that enroll ... Full text Link to item Cite

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.

Journal article J Clin Oncol · February 1, 2003 Featured Publication PURPOSE: To determine whether reverse transcriptase polymerase chain reaction (RT-PCR) to detect circulating prostate-specific antigen (PSA)-positive cells is a prognostic factor for survival in hormone refractory prostate cancer and to validate the progno ... Full text Link to item Cite

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

Journal article J Clin Oncol · August 15, 2002 Featured Publication PURPOSE: To test the hypothesis that the efficacy and toxicity of suramin in the treatment of patients with hormone-refractory prostate cancer was dose dependent. PATIENTS AND METHODS: Patients were randomized with equal probability to receive low-, interm ... Full text Link to item Cite

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.

Journal article J Clin Oncol · June 15, 2001 Featured Publication PURPOSE: To evaluate the prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) detection of prostate-specific antigen (PSA) mRNA in the blood of men with hormone-refractory prostate cancer (HRPC). PATIENTS AND METHODS: Periphe ... Full text Link to item Cite